Second Product
Not Specified
CommercialApproved (FDA & EU 2025)
Key Facts
About Insmed
Insmed is a patient-centric, global biopharma leader with a mission to deliver transformative therapies for serious and rare diseases. The company has achieved significant commercial and clinical milestones, including regulatory approvals and advanced late-stage pipelines, underpinned by a culture consistently recognized as a top employer. Its strategy hinges on deep patient collaboration, a synergistic technology platform spanning drug delivery and small molecules, and a disciplined focus on high-need pulmonary and rare disease markets.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| New TCM Formulations | China SXT Pharmaceuticals | Research / Pre-clinical |
| Long-acting Leronlimab | CytoDyn | Preclinical |
| Collaborative Program with Ferring | PharmaBiome | Research |
| Lighthouse Pilot Product | Cipherome | Pilot |
| Nitric Oxide + Collagen Delivery | Jellagen | Research |
| Undisclosed | Authera | Pre-clinical |
| mRNA Therapeutics Platform Application | Lupagen | Research |
| PHYRAGO | Handa Pharmaceuticals | Approved |
| TASCENSO ODT | Handa Pharmaceuticals | Approved |
| Axulin | Housey Pharmaceutical Research Laboratories | Commercial |
| PBI-04711 | Phoenix Biotechnology | Pre-clinical |
| Immunology Program | Ignite Biomedical | Discovery |